Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TVTX

+ Watchlist+ Portfolio

Travere Therapeutics, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$51.10
52-Week Range
$22.59 – $68.73
Market Cap
$4.82B
P/E (TTM)
—
EPS (TTM)
-1.67
Dividend Yield
0.00%
Advanced Metrics
Price/Book
212.88
PEG Ratio
—
Return on Equity
-321.22%
Return on Assets
-1.84%
Gross Margin
61.07%
Operating Margin
-3.13%
Profit Margin
-18.66%
Current Ratio
3.00
Debt/Equity
27.28
Total Debt
$616.16M
Free Cash Flow
$-64.79M
Revenue Growth
36.20%
Earnings Growth
—
Enterprise Value
$4.97B

Market Snapshot

About

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company has a commercial product for the treatment of IgA nephropathy and a pipeline of investigational therapies. Travere is committed to advancing treatments for patients with high unmet medical needs in rare diseases.